Stopping AOD 9604 has minimal documented effects because the compound does not alter appetite, hormones, or metabolic signaling
How does retatrutide differ from semaglutide and tirzepatide
Trials are investigating obesity, overweight with weight-related conditions, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease
For example, GLP-1s offer cardioprotective effects, likely mediated by improved endothelial function and reduced inflammation
Este beneficio fue mayor en los pacientes con macroalbuminuria66 (tabla 2)
The researchers did some pretty cool endocrine testing looking at GnRH pulsatility at the start of the study and after six months of taking 2g/day of ALC, a GnRH test to look at LH and FSH response to GnRH, and a TRH test (I have no idea what that is)